Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | PKM | P14618 | 3/20 | 0.70 |
| ▸ | HTT | P42858 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3111901 | 0.97 | ALDH1A1 (0.76) | ALDH1A1PKMHTTPOLBLMNA | |
| SCHEMBL23217199 | 0.97 | PKM (0.74) | ALDH1A1PKMHTTPOLBLMNA | |
| SCHEMBL3976265 | 0.95 | PKM (0.69) | ALDH1A1PKMHTTPOLBLMNA | |
| Bromide SCHEMBL1159786 | 0.95 | PKM (0.72) | ALDH1A1PKMHTTPOLBLMNA | |
| SCHEMBL5955341 | 0.93 | MAPT (0.69) | ALDH1A1PKMHTTPOLBLMNA | |
| SCHEMBL651924 | 0.93 | MAPT (0.69) | ALDH1A1PKMHTTPOLBLMNA | |
| SCHEMBL9122576 | 0.93 | MAPT (0.69) | ALDH1A1PKMHTTPOLBLMNA | |
| SCHEMBL3977980 | 0.92 | PKM (0.71) | ALDH1A1PKMHTTPOLBLMNA | |
| SCHEMBL3419433 | 0.92 | MAPT (0.67) | ALDH1A1PKMHTTPOLBLMNA | |
| Hydrochloric Acid SCHEMBL3244036 | 0.92 | ALDH1A1 (0.67) | ALDH1A1PKMHTTPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104744382-B | A kind of preparation method of homopiperazine | 渭南畅通药化科技有限公司 | 2017-09-15 | — | — | CN | claimed |
| CN-104744382-A | Preparation method of homopiperzine | WEINAN CHANGTONG PHARMACEUTICAL CHEMICAL CO LTD | 2015-07-01 | — | — | CN | claimed |
| US-20110129542-A1 | SUBSTITUTED AZEPINE- AND DIAZEPINE-SULFONAMIDES USEFUL TO INHIBIT 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1 | SCHERING CORPORATION | 2011-06-02 | — | — | US | claimed |
| EP-2190820-A2 | SUBSTITUTED AZEPINE- AND DIAZEPINE-SULFONAMIDES USEFUL TO INHIBIT 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1 | SCHERING CORPORATION (US) | 2010-06-02 | — | — | EP | claimed |
| WO-2009023664-A2 | SUBSTITUTED AZEPINE- AND DIAZEPINE-SULFONAMIDES USEFUL TO INHIBIT 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1 | SCHERING CORPORATION (US) | 2009-02-19 | — | — | WO | claimed |
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
| CN-104744382-B | A kind of preparation method of homopiperazine | 渭南畅通药化科技有限公司 | 2017-09-15 | — | — | CN | disclosed |
| CN-104744382-B | A kind of preparation method of homopiperazine | 渭南畅通药化科技有限公司 | 2017-09-15 | — | — | CN | disclosed |
| CN-104744382-A | Preparation method of homopiperzine | WEINAN CHANGTONG PHARMACEUTICAL CHEMICAL CO LTD | 2015-07-01 | — | — | CN | disclosed |
| US-20110129542-A1 | SUBSTITUTED AZEPINE- AND DIAZEPINE-SULFONAMIDES USEFUL TO INHIBIT 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1 | SCHERING CORPORATION | 2011-06-02 | — | — | US | disclosed |
| EP-2190820-A2 | SUBSTITUTED AZEPINE- AND DIAZEPINE-SULFONAMIDES USEFUL TO INHIBIT 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1 | SCHERING CORPORATION (US) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009023664-A2 | SUBSTITUTED AZEPINE- AND DIAZEPINE-SULFONAMIDES USEFUL TO INHIBIT 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1 | SCHERING CORPORATION (US) | 2009-02-19 | — | — | WO | disclosed |
| WO-2007056075-A2 | SIX MEMBERED HETEROAROMATIC INHIBITORS TARGETING RESISTANT KINASE MUTATIONS | TARGEGEN, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110129542-A1 | SUBSTITUTED AZEPINE- AND DIAZEPINE-SULFONAMIDES USEFUL TO INHIBIT 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1 | HSD11B1, HSD17B1, HSD3B1 | ALDH1A1 45/4885PKM 3613/4885HTT 4063/4885 |
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | ALDH1A1 4556/4885PKM 4535/4885HTT 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.